Icon
Icon plc, headquartered in Ireland (IE), is a leading global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990, Icon has established itself as a key player in the clinical research sector, with a strong presence across North America, Europe, and Asia. The company offers a comprehensive range of services, including clinical trial management, data analytics, and regulatory consulting, distinguished by its commitment to innovation and quality. Icon's unique approach integrates advanced technology and deep industry expertise, enabling clients to navigate the complexities of drug development efficiently. With a robust portfolio and a reputation for excellence, Icon plc has achieved significant milestones, including numerous successful product launches and partnerships with leading healthcare organisations, solidifying its position as a trusted partner in the life sciences industry.
DitchCarbon Score
How does Icon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Icon's score of 89 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Icon's reported carbon emissions
In 2024, ICON plc reported total carbon emissions of approximately 361,809,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 356,983,000 kg CO2e. Scope 1 emissions were approximately 2,357,000 kg CO2e, while Scope 2 emissions totalled about 2,469,000 kg CO2e (market-based). ICON has set ambitious climate commitments, aiming for a 61.2% absolute reduction in Scope 1 and 2 emissions by FY2028 from a FY2019 base year. Additionally, the company targets a 20.0% reduction in absolute Scope 3 emissions by FY2028 from a FY2022 base year. Long-term goals include a 90.0% reduction in both Scope 1 and 2 emissions by 2050, as well as a 90.0% reduction in Scope 3 emissions by the same year. These targets align with ICON's commitment to achieving net-zero greenhouse gas emissions across its value chain by FY2050, demonstrating a proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 1,827,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 18,796,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 36,726,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Icon is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
